Klebsiella pneumoniae Lipopolysaccharide Polysaccharide (O Antigen) Production Service

Features of Klebsiella pneumoniae

K. pneumoniae is an aerobic Gram-negative bacillus that colonizes a variety of hosts from plants to mammals and is one of the most common pathogens of community-acquired and nosocomial infections. Two distinct pathogenic types of K. pneumoniae are currently circulating globally: classic K. pneumoniae (cKp) and hypervirulent K. pneumoniae (hvKp). Compared with cKp, hvKP carries highly invasive and horizontally transferable virulence genes, which can cause more extensive and severe infections, such as suppurative liver abscess, meningitis, and necrotizing fasciitis, and can spread migratory.

Acquired antibiotic resistance genes and intrinsic resistance to several classes of antibiotics limit treatment options for infections caused by K. pneumoniae. For example, K. pneumoniae strain that produces extended-spectrum β-lactamase (ESBL) and K. pneumoniae carbapenemases (KPCs) can inactivate β-lactam antibiotics. Therefore, there is an urgent need to develop new therapeutics to prevent and treat K. pneumoniae infection.

Fig.1 Mechanisms of innate immunity to K. pneumoniae infections. (Bengoechea & Sa Pessoa, 2019)

K. pneumoniae Lipopolysaccharide Polysaccharide Production Service at CD BioGlyco

Capsular polysaccharide (K) and lipopolysaccharide (O) antigens are K. pneumoniae pathogens associated with nosocomial or community infections. In recent years we have included K. pneumoniae capsular polysaccharide (CPS) and lipopolysaccharide (LPS) in the development list of Polysaccharide Vaccines. LPS is a major component of the Gram-negative cell wall and plays an important role in outer membrane stability and protection from the external environment. It consists of lipid A molecule, core sugar, and terminal repeat O-antigen polysaccharide. Eleven characteristic LPS serogroups have been identified in K. pneumoniae, but 98% of isolates express only serotypes O1 to O4. These serogroups have similar LPS backbone structures. Therefore, developing agents targeting this structure may be a promising strategy.

We provide high-quality O-antigen development services for global clients. We will extract, purify, and characterize LPS from the surface of K. pneumonia, and conjugate it with Carrier Proteins such as bovine serum albumin (BSA) or Neisseria meningitidis outer membrane protein (OMP) to enhance immunogenicity according to the specific needs of clients.

Fig.2 Carrier protein conjugated to O antigen. (CD BioGlyco)

Advantages of Us

• We have developed a One-stop Solution for Polysaccharide Conjugation, including carrier protein design, polysaccharide production, and polysaccharide-carrier protein conjugation.
• We have developed various Techniques for Polysaccharide Conjugation with carrier proteins such as chemistry and physical crosslinking.
• An experienced expert team will design the experimental plan for you, and follow up and guide the development of the project.

CD BioGlyco has a well-equipped experimental platform and a professional team of scientists in the development of polysaccharide vaccines. We are committed to providing the highest quality Polysaccharide Antigen Development services for global enterprises, universities, and scientific research institutes. If you are interested in our O-antigen development services, please contact us for more details.

Reference:

1. Bengoechea, J.A.; Sa Pessoa, J. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS microbiology reviews. 2019, 43(2): 123-144.